Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-278-8930
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees321
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.45) by $0.15. View Atara Biotherapeutics' Earnings History.
When is Atara Biotherapeutics' next earnings date?
What price target have analysts set for ATRA?
10 brokers have issued 12 month target prices for Atara Biotherapeutics' shares. Their predictions range from $9.00 to $70.00. On average, they anticipate Atara Biotherapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 154.8% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.
What is the consensus analysts' recommendation for Atara Biotherapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.
What are Wall Street analysts saying about Atara Biotherapeutics stock?
Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (10/8/2019)
- 2. William Blair analysts commented, "We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant." (4/1/2019)
- 3. Mizuho analysts commented, "We note that this is not the first time the company has put an ATM in place." (2/26/2019)
Has Atara Biotherapeutics been receiving favorable news coverage?
Press coverage about ATRA stock has been trending negative recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Atara Biotherapeutics.
Are investors shorting Atara Biotherapeutics?
Atara Biotherapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 10,080,000 shares, an increase of 18.6% from the August 30th total of 8,500,000 shares. Based on an average daily volume of 821,700 shares, the short-interest ratio is currently 12.3 days. Approximately 21.2% of the company's shares are sold short. View Atara Biotherapeutics' Current Options Chain.
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Regenxbio (RGNX), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of Atara Biotherapeutics own?
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
- Mr. Utpal Koppikar, Chief Financial Officer (Age 49)
- Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
- Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)
- Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56)
How do I buy shares of Atara Biotherapeutics?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of ATRA stock can currently be purchased for approximately $12.17.
How big of a company is Atara Biotherapeutics?
Atara Biotherapeutics has a market capitalization of $653.97 million. The biotechnology company earns $-230,700,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.View Additional Information About Atara Biotherapeutics.
What is Atara Biotherapeutics' official website?
How can I contact Atara Biotherapeutics?
Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.
MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
